Latest news with #IOLs
Globe and Mail
26-06-2025
- Business
- Globe and Mail
Cataract Surgery Devices Market to Reach USD 10.97 Billion by 2030, Says Mordor Intelligence
Mordor Intelligence has published a new report on the Cataract Surgery Devices Market offering a comprehensive analysis of trends, growth drivers, and future projections. Introduction According to a 2025 report on Cataract Surgery Devices Market by Mordor Intelligence, the global market is expected to grow from USD 8.90 billion in 2025 to USD 10.97 billion by 2030, registering a CAGR of 4.27% during the forecast period. The cataract surgery devices market play a critical role in addressing one of the leading causes of visual impairment worldwide. Cataract surgery is a common and effective procedure, primarily performed on aging populations, to restore vision by removing the clouded natural lens and replacing it with an artificial intraocular lens (IOL). Over the years, the demand for cataract surgery has grown steadily, driven by rising life expectancy, increasing patient awareness, and improvements in surgical outcomes. As a result, the market for cataract surgery devices which includes equipment such as phacoemulsification machines, femtosecond lasers, ophthalmic viscoelastic devices (OVDs), and various types of IOLs has witnessed significant expansion. Key Market Trends Surge in premium intraocular lenses (IOLs) Intraocular lenses are the largest product segment, making up around 41.6 % of market revenues in 2024. Premium lens types such as multifocal, toric, aspheric, and light-adjustable IOLs are steadily gaining traction as patients and surgeons prioritize enhanced postoperative vision correction and reduced dependency on glasses Rapid growth in femtosecond laser-assisted cataract surgery Femtosecond laser systems is projected to register a robust CAGR through 2030, and femtosecond-laser-assisted surgery is expected to grow at around 5.98 % CAGR. These systems provide higher precision in capsulotomy and lens fragmentation, though they are priced at a premium. Steady innovations in phacoemulsification systems Phaco-based surgery held approximately XX.X% revenue share in 2024 Enhanced phaco devices now offer improved fluidics control, energy modulation, and ergonomic designs, aiming for shorter surgical times and smoother procedures. Rise of ambulatory surgery centers (ASCs) Hospitals currently account for about 42.7 % of the market, but ASCs are expected to grow faster with a % CAGR from 2025 to 2030. These centers are favored for their efficiency, lower per-care costs, and ability to handle higher patient throughput. Growing interest in AI and digital integration Though not deeply detailed in Mordor's figures, the report highlights increasing integration of AI-assisted surgical planning tools and digital guidance systems, particularly alongside femtosecond platforms. These technologies help surgeons optimize surgical flow and patient outcomes. Market Segmentation By Product Type Intraocular Lenses (IOLs) This is the largest segment, accounting for about % of market revenue in 2024. It includes monofocal, multifocal, toric, and aspheric lenses used to replace the eye's natural lens post-surgery. Femtosecond Laser Systems These systems facilitate laser-assisted cataract operations. Though still higher cost, they're projected to grow at a 6.43 % CAGR through 2030 due to their precision benefits. Phacoemulsification Equipment The standard ultrasonic devices for breaking up the cataract. These systems generate strong demand, especially in middle- and high-income regions due to volume requirements. Ophthalmic Viscoelastic Devices (OVDs) These gel-like substances are used during surgery to maintain eye structure and protect tissues. They form a significant part of consumables, supporting both phaco and laser-assisted workflows. By Surgery Technique Phaco-Based Standard Surgery The dominant surgical method, capturing roughly % of market revenue in 2024. Practitioners and facilities rely on proven ultrasonic protocols. Femtosecond Laser-Assisted Cataract Surgery (FLACS) A fast-growing sub-segment with a CAGR of around 5.98 % to 2030, driven by its automated capsulotomy and lens fragmentation advantages. By End User Hospitals The leading buyers of cataract surgery devices, representing of the market in 2024. They invest in full-scale OR setups with advanced equipment Ambulatory Surgery Centers (ASCs) These outpatient centers are expanding rapidly, with projected growth of about 5.87 % CAGR between 2025–2030. Their appeal lies in reduced cost and faster patient throughput. Ophthalmology Clinics This segment also invests in modern surgical systems, especially in urban settings of developing countries where patients increasingly expect high-standard vision care. By Geography North America The largest regional market, holding roughly % of global revenue in 2024 Asia-Pacific The fastest-growing region, with an anticipated CAGR of around % through 2030 Europe, Middle East & Africa, South America These areas together form the remainder of the market. Growth varies, with Europe under tighter regulation, the Middle East investing in eye-care centers, and Latin America impacted by economic fluctuations Major Players Alcon Inc. Holds a leading position, controlling approximately 80 % of cataract equipment installations and about 40 % of premium intraocular lens (IOL) sales globally In 2025, Alcon completed its acquisition of Lensar, gaining the ALLY dual-pulsed laser platform. Johnson & Johnson Vision (formerly Abbott Medical Optics) A key player with a strong IOL portfolio, its TECNIS lens line, including the Odyssey model, serves as a direct competitor to Alcon's AcrySof IQ Vivity. The company's scope spans surgical platforms, viscoelastics, and phacoemulsification systems. Carl Zeiss Meditec AG Well-known for its surgical precision tools, Zeiss leverages its VISUMAX refractive lasers alongside microscopes and digital connectivity solutions. Their systems aid in tracking outcomes for both cataract and corneal procedures Bausch + Lomb (Bausch Health) A significant force in both IOLs and ophthalmic Visco surgical devices. Its presence in multiple product lines ensures steady revenue across global markets. Nidek Co., Ltd. Among the top five manufacturers in the cataract space, Nidek has a notable footprint in surgical devices and diagnostics Conclusion The cataract surgery devices market is set for sustained growth, supported by the rising prevalence of age-related vision disorders, especially among aging populations worldwide. As demand for improved visual outcomes and quicker recovery increases, the adoption of advanced surgical tools such as femtosecond laser systems and premium intraocular lenses is expected to rise steadily. Industry Related Reports Ophthalmic Surgical Devices Market: The Ophthalmic Surgical Devices Market Report is segmented by Product (Refractive Surgery Devices, Glaucoma Surgery Devices, Cataract Surgery Devices, and Other Surgical Devices), End User (Hospitals, Specialty Ophthalmic Clinics, Ambulatory Surgery Centers (ASCs), and Other End Users), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The market forecasts are provided in terms of value (USD). Ophthalmic Visco surgical Devices Market : The Ophthalmic Visco surgical Devices Market is segmented by Type (Cohesive, Dispersive, and Viscoadaptive), Source (Biological, Animal, and Semi-synthetic), Application (Glaucoma Surgery, Cataract Surgery, Corneal Grafting, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market forecasts are provided in terms of value (USD million) for the above segments. Germany Ophthalmic Devices Market : The Germany Ophthalmic Devices Market Report is segmented by Device Type (Diagnostic & Monitoring Devices, Surgical Devices, and Vision Care Devices), Disease Indication (Cataract, Glaucoma, Diabetic Retinopathy, and Other Disease Indications), and End User (Hospitals, Specialty Ophthalmic Clinics, Ambulatory Surgery Centers (ASCs), and Other End Users). The market forecasts are provided in terms of value (USD). About Mordor Intelligence: Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. For any inquiries or to access the full report, please contact: media@
Business Wire
20-06-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding BLCO should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Bausch + Lomb Corporation (BLCO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAUSCH + LOMB CORPORATION (BLCO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you purchased BLCO securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
08-05-2025
- Business
- Business Wire
Securities Fraud Investigation Into Bausch + Lomb Corporation (BLCO) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation ('BLCO' or the 'Company') (NYSE: BLCO) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON BAUSCH + LOMB CORPORATION (BLCO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is the Investigation About? On March 27, 2025, BLCO disclosed that it had '[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)' and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses. On this news, BLCO's stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors. Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that 'as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.' On this news, BLCO's stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further. Contact Us to Participate or Learn More: If you purchased BLCO securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
